NASDAQ:SNGX - Soligenix News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.8971 -0.04 (-4.27 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$0.8971
Today's Range$0.8971 - $0.9379
52-Week Range$0.80 - $3.70
Volume19,681 shs
Average Volume245,216 shs
Market Capitalization$14.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26

Headlines

Soligenix (NASDAQ SNGX) News Headlines

Source:
DateHeadline
SNGX: Innate Defense Regulators Offer New Approach to Treating InfectionsSNGX: Innate Defense Regulators Offer New Approach to Treating Infections
finance.yahoo.com - February 12 at 7:22 PM
Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®
finance.yahoo.com - February 11 at 8:26 AM
 Soligenix, Inc. (SNGX) Given $6.25 Average Target Price by Analysts Soligenix, Inc. (SNGX) Given $6.25 Average Target Price by Analysts
www.americanbankingnews.com - February 8 at 10:07 AM
Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine CandidateSoligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
finance.yahoo.com - February 7 at 8:16 AM
Soligenix nabs new patent in EuropeSoligenix nabs new patent in Europe
seekingalpha.com - January 23 at 8:11 AM
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator AnalogsSoligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
www.prnewswire.com - January 23 at 6:37 AM
Soligenix to raise $611K via sale of NJ tax creditsSoligenix to raise $611K via sale of NJ tax credits
seekingalpha.com - December 11 at 8:31 AM
Soligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer ProgramSoligenix to Receive $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
finance.yahoo.com - December 11 at 8:31 AM
Soligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator TechnologySoligenix Announces Publication of Scientific Review Discussing Clinical Applications of Innate Defense Regulator Technology
finance.yahoo.com - December 5 at 8:13 AM
Soligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, MarylandSoligenix Selected to Present RiVax® Data at the Fourth International Conference on Vaccines Research & Development in Baltimore, Maryland
finance.yahoo.com - November 12 at 8:18 AM
Soligenix EPS in-line, beats on revenueSoligenix EPS in-line, beats on revenue
seekingalpha.com - November 9 at 8:17 AM
SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success…SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success…
finance.yahoo.com - October 16 at 5:01 PM
SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301
finance.yahoo.com - October 15 at 5:09 PM
Soligenix to increase enrollment in late-stage study of SGX301 in CTCLSoligenix to increase enrollment in late-stage study of SGX301 in CTCL
seekingalpha.com - October 15 at 8:16 AM
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell LymphomaSoligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
finance.yahoo.com - October 15 at 8:16 AM
Soligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough SummitSoligenix Announces Poster Presentations of its Ricin Vaccine and Dusquetide Oral Mucositis Programs at the 2018 NORD Rare Diseases and Orphan Products Breakthrough Summit
finance.yahoo.com - October 4 at 8:12 AM
SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?
finance.yahoo.com - September 14 at 5:03 PM
NIH selects Soligenixs SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator ProgramNIH selects Soligenix's SGX942 in the Treatment of Oral Mucositis for the Commercialization Accelerator Program
finance.yahoo.com - September 13 at 8:20 AM
Soligenix to Present at BioCenturys 25th Annual NewsMakers in the Biotech IndustrySoligenix to Present at BioCentury's 25th Annual NewsMakers in the Biotech Industry
finance.yahoo.com - September 5 at 8:18 AM
Soligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin VaccineSoligenix Announces Publication of Positive Long-Term Data Supporting Thermostability and Conformational Integrity of the RiVax® Ricin Toxin Vaccine
finance.yahoo.com - September 4 at 8:21 AM
Soligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial ResistanceSoligenix to Present at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
finance.yahoo.com - August 29 at 8:23 AM
Soligenix Receives US Patent for Improved Production of Synthetic HypericinSoligenix Receives US Patent for Improved Production of Synthetic Hypericin
finance.yahoo.com - August 22 at 8:18 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Soligenix, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - August 13 at 8:10 AM
Soligenix Announces Recent Accomplishments And Second Quarter 2018 Financial ResultsSoligenix Announces Recent Accomplishments And Second Quarter 2018 Financial Results
finance.yahoo.com - August 8 at 8:19 AM
Soligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, CanadaSoligenix Announces a RiVax® Program Presentation at the 31st Annual Congress on Vaccines, Clinical Trials & B2B in Vancouver, Canada
finance.yahoo.com - July 26 at 8:14 AM
Soligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) FormulationSoligenix Receives European and Canadian Patents for its Ricin Toxin Vaccine (RiVax®) Formulation
finance.yahoo.com - July 9 at 8:12 AM
SNGX: New Financing Boosts Balance SheetSNGX: New Financing Boosts Balance Sheet
finance.yahoo.com - July 6 at 4:48 PM
Soligenix, Inc. Prices $8,000,000 Public Offering At The MarketSoligenix, Inc. Prices $8,000,000 Public Offering At The Market
finance.yahoo.com - June 28 at 8:34 AM
Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, GeorgiaSoligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia
finance.yahoo.com - June 12 at 8:15 AM
Soligenix Inc’s (NASDAQ:SNGX) Shift From Loss To ProfitSoligenix Inc’s (NASDAQ:SNGX) Shift From Loss To Profit
finance.yahoo.com - May 25 at 5:57 PM
SNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola VaccineSNGX: ThermoVax Technology May be the Solution of Developing Heat Stable Ebola Vaccine
finance.yahoo.com - May 23 at 5:40 PM
Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial ResultsSoligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results
finance.yahoo.com - May 11 at 8:18 AM
Soligenix to Present at the NYC Oncology Investor Conference 2018Soligenix to Present at the NYC Oncology Investor Conference 2018
finance.yahoo.com - May 7 at 8:15 AM
Soligenix, Inc. (SNGX) Granted Orphan Drug Designation from European Commission for RiVax for Prevention of Ricin PoisoningSoligenix, Inc. (SNGX) Granted Orphan Drug Designation from European Commission for RiVax for Prevention of Ricin Poisoning
www.streetinsider.com - March 23 at 8:15 AM
28 Stocks Moving In Thursdays Mid-Day Session28 Stocks Moving In Thursday's Mid-Day Session
feeds.benzinga.com - March 22 at 2:31 PM
Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin PoisoningSoligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
finance.yahoo.com - March 22 at 8:21 AM
Soligenix Announces Recent Accomplishments And Year-End 2017 Financial ResultsSoligenix Announces Recent Accomplishments And Year-End 2017 Financial Results
finance.yahoo.com - March 15 at 8:12 AM
Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical TrialsSoligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
www.prnewswire.com - January 25 at 8:02 AM
Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral MucositisBlog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis
finance.yahoo.com - January 4 at 11:01 AM
Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
finance.yahoo.com - December 21 at 3:46 PM
Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
www.prnewswire.com - December 21 at 6:26 AM
Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed LatelyWant To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately
finance.yahoo.com - December 8 at 3:50 PM
Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CASoligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA
finance.yahoo.com - November 27 at 4:13 PM
Who Owns Most Of Soligenix Inc (SNGX)?Who Owns Most Of Soligenix Inc (SNGX)?
finance.yahoo.com - November 15 at 10:06 AM
Soligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above MarketSoligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
finance.yahoo.com - November 4 at 4:05 PM
Soligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine CandidateSoligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate
finance.yahoo.com - September 27 at 8:44 AM
Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 23 at 7:31 AM
Soligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III TrialsSoligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III Trials
finance.yahoo.com - September 23 at 7:31 AM
Soligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing BellSoligenix, Inc. (Nasdaq: SNGX) to Ring The Nasdaq Stock Market Closing Bell
feeds.benzinga.com - August 30 at 11:13 AM
Soligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoingSoligenix Begins Patient Enrollment for Pivotal Phase 3 Trial (SGX942) for Oral Mucositis & Enrollment in Phase III of SGX301 ongoing
finance.yahoo.com - August 2 at 4:38 PM
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel